Navigation Links
Positron Recieves Indiana Board of Pharmacy License
Date:12/19/2011

FISHERS, Ind., Dec. 19, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce that on December 16, 2011, the Company received a nuclear pharmacy license from the Indiana Board of Pharmacy for the Company's Crown Point, Indiana manufacturing facility.

The Indiana Board of Pharmacy license completes the requirements necessary to amend its NRC license to allow Positron to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the United States.  The Company will begin to produce Indium 111 Oxyquinoline for customer evaluation and commercial sale.

"We are pleased to receive this approval as it will allow our Crown Point facility to become fully licensed and operational as a radiochemical manufacturing facility," said Scott Stiffler, Positron's Vice President of Pharmaceuticals. "The Crown Point facility provides an ideal site for the manufacturing and development of radiopharmaceuticals and radiochemicals.  The revenue generated from our Indium Oxyquinoline sales will allow Positron to expand its current product offerings. I'm pleased with the team's efforts and execution at Crown Point of this significant milestone."

About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology.  Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine.  Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Positron Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
2. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
3. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
4. New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors
5. Alliance Imaging Offers Mobile Positron Emission Mammography (PEM) Imaging to its Florida Customers
6. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
7. Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
8. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
9. Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015
10. Naviscan Announces European Launch of Positron Emission Mammography
11. Study Shows Positron Emission Mammography (PEM) is Easy for Breast Imagers to Learn Regardless of Experience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Md. , Aug. 7, 2017 ... healthcare member acquisition, retention, and engagement, announced the ... of Strategy and Product Development, effective as of ... consulting and technology implementation strategy for our clients. ... of experience in consulting and business analytics within ...
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
(Date:8/7/2017)...  Endo International plc (NASDAQ: ENDP ) ... all known U.S. mesh product liability claims and that ... remaining U.S. claims at reasonable values. Under the agreements, ... quarter of 2017 and continuing through the fourth quarter ... results, the Company intends to increase its mesh product ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active patients, ... replacement therapy and integrative medicine, has become a frontrunner for people seeking help ... menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by ...
(Date:8/18/2017)... ... August 18, 2017 , ... Inc. magazine has ranked American ... prestigious ranking of the nation's fastest-growing private companies. This marks the eighth time in ... 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue growth from ...
(Date:8/18/2017)... ... ... “Dangerous Inheritance”: a mystery about saving the family farm. “Dangerous Inheritance” ... where she was raised on a farm. As Diane wrote this story, she ... friendships and mantra of ‘neighbors helping neighbors’ have always been a large part of ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the ... to reflect upon the stories and the relevance these tales may have on the ... Jessica Linhart, a former special education teacher, Jessica spends much of her time enjoying ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Prompted By Love”: a love story thrown into ... Mary Nettles. Author Mary P. Nettles has devoted her life to ministry since ... Her lifelong desire to write was, however, not fulfilled until 2014 when "The Color ...
Breaking Medicine News(10 mins):